The PD-1/PD-L1 signaling pathway has been in the spotlight in the recent years as its blockade with checkpoint inhibitor therapy in several tumour types including TNBCs re-engages the immune response leading to prolonged survival [33–35]. Here, CD274 is linked to neoplasm.